Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 405 for:    ARIPIPRAZOLE

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole (DIMES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03881449
Recruitment Status : Recruiting
First Posted : March 19, 2019
Last Update Posted : May 17, 2019
Sponsor:
Collaborator:
Otsuka Pharmaceutical Development and Commercialization, Inc.
Information provided by (Responsible Party):
Durham VA Medical Center

Brief Summary:

This is a 12 month, pragmatic trial designed to assess the differences in a digital medicine system (DMS)- ABILIFY MYCITE (Aripiprazole tablets with sensor)- measuring adherence versus treatment as usual (TAU) for adult patients with schizophrenia, bipolar I disorder, and major depression. Outcomes of interest will be adherence as measured by refill rates and all-cause and psychiatric health care use. Each patient will be in the study for a duration of 12 months.

All treatment medication decisions will be made by the healthcare professionals (HCPs) and not by protocol. Psychiatrist(s), nurse(s) and/or team manager(s) who will be responsible for subjects' care, will be considered as HCPs in this trial.


Condition or disease Intervention/treatment Phase
Schizophrenia Major Depressive Disorder Bi-Polar Disorder Schizo Affective Disorder Combination Product: ABILIFY MYCITE Phase 4

Detailed Description:

This is a phase 4, 12-month, pragmatic trial designed to assess adherence in patients using ABILIFY MYCITE versus patients receiving treatment as usual (TAU). Both groups will complete surveys at baseline, 90, 180, and 360 days and will receive care at the discretion of their physician. The usual care group will not receive the ABILIFY MYCITE intervention. The primary outcome will assess refill rates at 6 months.

Eligible patients will enroll at their screening/baseline visit and ABILIFY MYCITE onboarding will be provided in the clinic, with commercial informational materials and additional call center support. Patients will then initiate 3 months of treatment with ABILIFY MYCITE at the baseline visit. At the Day 90 visit, patients will have the opportunity to either stop or continue using ABILIFY MYCITE for the remainder of the study (9 months). This decision must be a joint decision with the patient and his or her treating physician. During this optional interventional phase, patients may start and stop ABILIFY MYCITE as clinically indicated.

All enrolled patients will have required in-person visits at baseline, 90-days, and 180-days. The day 360 (final) visit can be in-person or via telephone.

Medical and actual pharmacy dispensing data will be collected from day 1 through day 360 using the VA's electronic medical record system.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is an open-label 2-site (Durham and Houston Veterans Affairs (VA) Health Care Systems), provider randomized, prospective 2-arm (intervention vs. TAU) pragmatic trial. We will enroll 300 adult patients with schizophrenia, bipolar I disorder, or major depressive disorder currently being treated with oral Aripiprazole from either the Durham, North Carolina or Houston, Texas Veterans Affairs (VA) Health Care System.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole
Actual Study Start Date : April 4, 2019
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: ABILIFY MYCITE Group

If patients are assigned to the ABILIFY MYCITE treatment group, the patients and physician will initiate the system at the baseline visit, and continue to use the system for 3 months. At any time after the first 3 months, a patient and his or her doctor will have the opportunity to either discontinue or continue using ABILIFY MYCITE for the remainder of the trial (9 additional months; 12 months total) as long as clinically appropriate with the goal of measuring adherence to improve clinical decision-making and care.

Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months.

Combination Product: ABILIFY MYCITE
Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.

No Intervention: Treatment as Usual (TAU) Group

TAU patients will continue receiving care as recommended by their physician which will include the use of Aripiprazole according to the approved labels.

Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months.




Primary Outcome Measures :
  1. Aripiprazole refills [ Time Frame: 6 months ]
    Aripiprazole refill as operationalized as a continuous measure of the number of days covered over the baseline to 6 month period


Secondary Outcome Measures :
  1. Population Proportion of Days Covered (PDC) [ Time Frame: 12 months ]
    The secondary outcomes of medication adherence (to Aripiprazole and other psychotic medications), defined as a binary indicators that PDC ≥ 80% for the prior 30-day period, are collected at baseline, 3, 6, and 12 months.

  2. Days in acute care settings [ Time Frame: 12 months ]
    The measure of days in acute care (i.e., days not in the community) over the 12-month outcomes interval defined as the total number of days in the ED or inpatient ward.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 18 years of age or older.
  • Patients with a primary diagnosis of schizophrenia (including schizoaffective disorder), bipolar I disorder, or major depressive disorder based on the Diagnostic Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria.
  • Patients have an active prescription for oral Aripiprazole.
  • Patients may have general medical conditions that are deemed safe for the patient to enter an interventional trial per investigator judgment.
  • Patients deemed fit for participation in the study by verbal or written confirmation from their mental health provider

Exclusion Criteria:

  • Patients with a current neurocognitive disorder (i.e. dementia), intellectual disorder, or any other diagnosis that could impact the patient's ability to participate in the trial.
  • Any patient who, in the opinion of the patient's mental health provider, study physician or investigator, is unfit to participate in the trial.
  • Any patient who has participated in an investigational drug trial 30 days prior to trial enrollment.
  • Females who are breastfeeding, and/or who have a positive pregnancy test prior to trial enrollment, or females who are planning to become pregnant during the trial. No clinical trials have been conducted on the use of ABILIFY MYCITE during pregnancy or breastfeeding.
  • Patients who do not have skin on the anterior chest just above the lower edge of the rib cage that is free of any dermatological problems (e.g., dermatosis or dermatitis, open wounds, or other skin disorders such as warts, rashes, atopic dermatitis, or irritations).
  • Patients who are unwilling to refrain from the use of topical products on the skin patch sites.
  • Has 2 or more errors on the brief, 6-item cognitive screener administered at baseline.
  • <20% Proportion of Days Covered (PDC) Aripiprazole over the last 6 months prior to enrollment. This is to ensure that all individuals enrolled will have at least filled their Aripiprazole prescription.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03881449


Contacts
Layout table for location contacts
Contact: Sarah Gonzales, BA 919-668-1226 sarah.gonzales3@va.gov
Contact: Megan Oakes, MS 919-669-0966 megan.oakes15@va.gov

Locations
Layout table for location information
United States, North Carolina
Durham VA Medical Center Recruiting
Durham, North Carolina, United States, 27705
Contact: Sarah Gonzales    919-668-1226    sarah.gonzales3@va.gov   
Contact: Megan Oakes, MS    919-668-0966    Megan.Oakes15@va.gov   
Principal Investigator: Hayden Bosworth, PhD         
Sub-Investigator: Scott Moore, MD         
United States, Texas
Michael E. DeBakey VA Medical Center Not yet recruiting
Houston, Texas, United States, 77030
Contact: Cristin Rodriguez    713-798-7786    Cristin.Rodriguez@bcm.edu   
Principal Investigator: Raymond Cho, MD         
Sub-Investigator: Olaoluwa Okusaga, MD         
Sponsors and Collaborators
Durham VA Medical Center
Otsuka Pharmaceutical Development and Commercialization, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Hayden Bosworth, PhD Durham VA Medical Center

Layout table for additonal information
Responsible Party: Durham VA Medical Center
ClinicalTrials.gov Identifier: NCT03881449     History of Changes
Other Study ID Numbers: 02188
First Posted: March 19, 2019    Key Record Dates
Last Update Posted: May 17, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Durham VA Medical Center:
digital medicine

Additional relevant MeSH terms:
Layout table for MeSH terms
Aripiprazole
Disease
Depression
Schizophrenia
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Psychotic Disorders
Bipolar Disorder
Pathologic Processes
Behavioral Symptoms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Bipolar and Related Disorders
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Dopamine D2 Receptor Antagonists